Application of Mycophenolate Mofetil in Renal Transplantation treatment window
Recently, Nanfang hospital, Southern Medical University organ transplant researchers published papers to determine application of Mycophenolate Mofetil in kidney transplant recipients (MMF) a reasonable therapeutic window concentration. Study on kidney transplant recipients taking MMF MPA-C0 monitoring, individual adjustments to the MMF, to prevent the occurrence of acute rejection and drug toxicity, reducing complications and improving the survival rate of transplanted kidney and recipient. This paper was published in 2014 on the 12th issue of the southern medical journal at the University. Selected 110 cases kidney transplant by who respectively Yu operation Hou January within, and 2-3 months, and > 4 months application enzyme zoom immune analysis technology determination oral MMF (points two times taking, interval 12 h) 12 h Hou full blood Valley concentration (that MPA-C0), and observation by who medication during acute exclusion reaction and the drug HIV side occurred situation, on all by who follow-up time are for 1 years. Statistical data show that incidence of acute rejection after surgery was 13.64% (15/110), the incidence of drug toxicity for 32.73% (36/110), 12 cases of leukopenia, MMF-associated diarrhea 10, 10 cases of infection, liver damage 4. Methylprednisolone in acute rejection occurs after treatment with methylprednisolone were successfully reversed by drug toxicity from treatment and (or) after adjusting the MMF-dose recovery, removal of no deaths and kidney transplant cases. Calculated by ROC curves, 1.40~2.80 mg/L MPA-C0 control can be used to avoid acute rejection after Renal Transplantation and reduce drug toxicity.